BioWorld

July 20, 2005

View Archived Issues

$525M Gets Emtriva Interest From Emory For Gilead, Royalty Pharma

Gilead Sciences Inc. and Royalty Pharma bought out Emory University's royalty interest in emtricitabine - or Emtriva - for $525 million. (BioWorld Today) Read More

After Long Wait, Crawford Confirmed As Head Of FDA

Read More

Arakis Providing Exit Via £106.5M Sosei Acquisition

Read More

Ilypsa's Series B Adds $36M For Renal Disease Products

Read More

Correction

Read More

Other News To Note

Read More

Appointments And Advancements

Read More